
Kd, Ki, IC50, and EC50 answer different experimental questions. Kd describes equilibrium binding, Ki is an inhibition constant inferred from a specified model, IC50 is the concentration producing 50% inhibition in a specified assay, and EC50 is the concentration producing 50% of a defined functional response. Do not treat them as one scale of peptide potency: first identify the assay, endpoint, and model behind each value.
What each value answers

| Value | What it describes | Question it helps answer | Main interpretation limit |
|---|---|---|---|
| Kd | Equilibrium dissociation constant for a ligand–target interaction | What equilibrium binding constant describes this ligand–target system under the stated model? | It depends on a valid binding model and conditions such as reaching equilibrium and avoiding material ligand depletion. |
| Ki | Inhibition constant inferred from a specified competition or inhibition model | What model-based constant describes inhibition or competitor affinity in this assay? | It depends on the model and inputs; it is not simply the measured IC50 or automatically a Kd. |
| IC50 | Concentration that produces 50% inhibition in a particular assay | At what concentration does this assay’s measured signal reach 50% inhibition? | It varies with assay conditions and is not a universal affinity constant. |
| EC50 | Concentration that produces 50% of a defined functional response | At what concentration does this system reach half of the response used for the analysis? | It depends on the biological system, endpoint, and response model; it does not by itself measure binding affinity. |
Binding studies and response studies connect ligand concentration to different outcomes. A binding experiment measures target occupancy or tracer displacement under its chosen conditions. A functional assay measures an output such as a signaling response. Models can relate these observations, but the relationship depends on the assumptions used. [1]
Kd and Ki: binding parameters with model conditions
Kd is an equilibrium parameter for a ligand binding to a target. Its interpretation requires that the experiment and analysis support an equilibrium binding estimate. Failure to reach equilibrium, ligand depletion, limits of the tracer-binding setup, buffer composition, and temperature can affect affinity estimates. [2]
Ki is an inhibition constant inferred under a specified competition or inhibition model. In a binding assay it may serve as an affinity-related estimate, but the label alone does not make it interchangeable with Kd. Check which interaction was modeled, what tracer or substrate was used, and how the value was derived.
When reading either value, look for the target and assay format, ligand or tracer conditions, buffer and temperature, evidence that equilibrium was reached, and the analysis model. If these are missing, the value may still describe the original experiment, but the report provides too little context for a reliable comparison.
IC50: a result from a specified inhibition assay
IC50 is the concentration at which the assay’s measured inhibition reaches 50% under the reported conditions. That result depends on what the assay measures and how it is run. In competitive binding, tracer concentration and tracer affinity enter the IC50-to-Ki calculation; a reported IC50 alone does not establish an intrinsic binding constant.
For an equilibrium competitive binding assay, a common Cheng–Prusoff transformation is Ki = IC50 / (1 + [L] / Kd,L), where [L] is the concentration of labeled tracer and Kd,L is that tracer’s dissociation constant. The transformation depends on the competitive model and valid equilibrium/tracer conditions; it is not a general conversion for functional-response assays or allosteric interactions. [2] Do not calculate Ki unless the assay matches those assumptions and the required inputs are available.
EC50: a functional-response value
EC50 is the concentration associated with 50% of a defined functional response, such as a signaling endpoint in a particular experimental system. It describes potency in that assay, not binding affinity by itself. The response model and the system expressing the target affect how the concentration–response curve relates to binding. [1]
One possible reason response potency and binding affinity can differ is receptor reserve: a system may produce a measurable response without occupying every receptor. A review focused on adenosine receptors discusses suspecting spare receptors when response EC50 is below ligand affinity Kd. That is a context-specific interpretation, not a rule that establishes receptor reserve in every peptide assay. [3]
Published peptide-receptor example: binding and cAMP response

Dods and Donnelly studied peptide agonists at the glucagon-like peptide-1 receptor (GLP-1R) using radioligand competition binding and functional cAMP assays. For the K288A receptor mutation, the study reported a 5,289-fold reduction in functional potency and a 23-fold reduction in binding affinity. [4]
| Study observation | What it supports | What it does not establish |
|---|---|---|
| Binding and cAMP response were measured with separate assays. | The study assessed binding and function as distinct readouts. | That the two values can be converted into each other. |
| The K288A mutation affected functional potency and binding affinity by different reported amounts. | In this GLP-1R study, a mutation’s effect on response was not numerically the same as its effect on binding. | A general relationship for other receptors, peptides, assay systems, or research materials. |
This is one receptor and study context. It is not a result for any commercial product or batch, and the reported fold changes should not be used as a general conversion between binding affinity and functional potency.
Checklist for comparing reported values
Related research: Designing Peptide Receptor Assays: Controls, Readouts, and Common Interpretation Traps; From Cell Studies to Animal Models: An Evidence Framework for Research Peptides; Peptide Stability Claims: What Batch-Specific Evidence Should Support Them.
Before comparing two values, check:
- What was measured? Identify binding, inhibition, or functional response, including the specific endpoint.
- Which target and system were used? Record the receptor or enzyme and, for functional studies, the biological system.
- What conditions shaped the measurement? Check tracer or substrate, concentrations, incubation and equilibrium conditions, buffer, and temperature where reported.
- How was the value estimated? Identify the analysis model and whether a reported Ki was calculated from an IC50.
- Are the experiments comparable? Values from different assay formats or endpoints need not represent the same property, even when their labels match.
- What is missing? If key conditions or model details are absent, state that the comparison is limited instead of assuming they are equivalent.
References
- Finlay DB, Duffull SB, Glass M. “100 years of modelling ligand–receptor binding and response: A focus on GPCRs.” *British Journal of Pharmacology*, 2020.
- Hulme EC, Trevethick MA. “Ligand binding assays at equilibrium: validation and interpretation.” *British Journal of Pharmacology*, 2010.
- Guieu R, et al. “Adenosine Receptor Reserve and Long-Term Potentiation: Unconventional Adaptive Mechanisms in Cardiovascular Diseases?” *International Journal of Molecular Sciences*, 2021.
- Dods RL, Donnelly D. “The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling.” *Bioscience Reports*, 2015.
Research Use Only Disclaimer
This article is for laboratory and analytical education only. It is not a validated experimental protocol or medical or veterinary advice. Nothing here is intended to guide administration to people or animals, diagnosis, or treatment.